Biocon Biologics Appoints Kedar Upadhye as New CFO replacing M B Chinappa
Chinappa participated in a number of important strategic projects, including Biocon’s successful IPO in 2004, he will transition into a position in strategic finance and collaborate with Peter Bains, Biocon’s recently recruited Group CEO
Biocon Biologics (BBL) appointed Kedar Upadhye as the new Chief Financial Officer (CFO), effective from 31 October 2023. He will replace MB Chinappa who will now transition take on a strategic finance role at Biocon Group, stated the press release.
Chinappa joined the Biocon Group in 1999 as a significant member of the Finance Leadership Team. There, he participated in a number of important strategic projects, including Biocon’s successful IPO in 2004. He will transition into a position in strategic finance and collaborate with Peter Bains, Biocon’s recently recruited Group CEO.
“I would like to thank Chinappa for his immense contribution to Biocon Biologics over the past 3 years and to the Biocon Group for more than two decades. He has successfully built a strong foundation of fiscal prudence, financial governance and risk management,” said Shreehas Tambe, Chief Executive Officer and Managing Director, Biocon. Chinappa has made the company successful by contributing significantly to the multi-billio- dollar acquisition of Viatris’ global biosimilars business, he added.